Purpose Patients with Atrial Fibrillation (AF) and prior stroke are classified as high risk in all
risk stratification schemes. A systematic review and meta-analysis was performed to …

Direct oral anticoagulants (DOACs) have increasingly replaced warfarin for treating patients
with non‐valvular atrial fibrillation (NVAF). DOACs have been demonstrated to be more …

Direct-acting oral anticoagulants (DOACs) are replacing conventional VKA (vitamin K
antagonist, ie, warfarin) for various indications where a therapeutic anticoagulant effect is …

Recent findings require an update of previous recommendations for the perioperative use of
Direct Oral AntiCoagulants (DOACs). A break in preoperative treatment of 24–96 hours is …

In recent years, small oral compounds that specifically block activated coagulation factor X
(FXa) or thrombin (FIIa) have become alternatives to the anticoagulants that had been used …

In recent years, the options for anticoagulant therapy have examined new direct oral
anticoagulants (DOACs) comprising direct thrombin inhibitors (dabigatran) and direct factor …

Background A number of novel oral anticoagulants (direct thrombin inhibitors or factor Xa
inhibitors) are in clinical use for various indications. The dosing regimens differ between …

What is known and objective Oral anticoagulants (OAC s) have been used for decades for
the long‐term prevention of arterial and venous thromboembolic disease. These include …

Direct oral anticoagulants have been an increasingly used class of drugs in the setting of
nonvalvular atrial fibrillation, defying vitamin K antagonists' monopoly when it comes to …

Background Direct oral anticoagulants (DOACs) have expanded the armamentarium for
antithrombotic therapy. Although DOAC-related major bleeding was associated with …